

FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8
DICTIONARY FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10577334.str



chain nodes :

12 49

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31 32 33 34 35 36 41 42 43 44 45 46

ring/chain nodes :

10

chain bonds :

12-49

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29
29-30 31-32

31-36 32-33 33-34 34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46

exact/norm bonds :

5-7 6-9 7-8 8-9 12-49

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24
20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36
32-33 33-34
34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46

G1:[*1],[*2],[*3],[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 49:CLASS
50:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s ll sss sam
SAMPLE SEARCH INITIATED 09:12:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22304 TO ITERATE


9.0% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 437137 TO 455023
PROJECTED ANSWERS: 322 TO 1016

L2 3 SEA SSS SAM L1

=> d scan


L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)-
MF C28 H34 N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazole-5-carboxamide, 6-(3,5-dimethyl-1-piperazinyl)-N-1H-indazol-6-yl-2-[[2-(trifluoromethyl)phenyl]amino]-
MF C28 H27 F3 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s ll sss full
FULL SEARCH INITIATED 09:12:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 448427 TO ITERATE

100.0% PROCESSED 448427 ITERATIONS 586 ANSWERS
SEARCH TIME: 00.00.08

L3 586 SEA SSS FUL L1

=> file capl
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 09:13:01 ON 10 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2009 VOL 151 ISS 20
FILE LAST UPDATED: 9 Nov 2009 (20091109/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAPLUS family databases for free! Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.

=> s 13
L4 51 L3

=> s 14 and (pd<20041027 or prd<20041027 or ad<20041027)

25028355 PD<20041027
(PD<20041027)
4549516 PRD<20041027
(PRD<20041027)
5072655 AD<20041027
(AD<20041027)

L5 36 L4 AND (PD<20041027 OR PRD<20041027 OR AD<20041027)

=> d 1-36 ibib hitstr

L5 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:576501 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 150:515173

TITLE: Preparation of fused azoles such as 2,5-disubstituted
benzimidazoles, benzoxazoles and benzothiazoles as
kinase inhibitors

INVENTOR(S): Di Pietro, Lucian V.; Harmange, Jean-Christophe;
Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie;
Habygood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.;
Potashman, Michele; Van Der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S., 95pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7531553	B2	20090512	US 2004-804915	20040319 <--
US 20040209892	A1	20041021		
AU 2004223827	A1	20041007	AU 2004-223827	20040322 <--
AU 2004223827	B2	20080306		
CA 2518909	A1	20041007	CA 2004-2518909	20040322 <--
WO 2004085425	A1	20041007	WO 2004-US8809	20040322 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

EP 1638954 A1 20060329 EP 2004-758050 20040322 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
JP 2006520805 T 20060914 JP 2006-507472 20040322 <--
MX 2005010086 A 20060210 MX 2005-10086 20050921 <--
PRIORITY APPLN. INFO.: US 2003-456691P P 20030321 <--
US 2004-804915 A 20040319 <--
WO 2004-US8809 A 20040322 <--


IT 1055984-37-6P 1055984-58-1P 1055984-62-7P
1055985-13-1P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as
kinase inhibitors)
RN 1055984-37-6 CAPLUS
CN 3-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-
yl]amino]-N-methyl- (CA INDEX NAME)




RN 1055984-58-1 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-
quinolinyl)- (CA INDEX NAME)



RN 1055984-62-7 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-[2-(methylamino)-
4-pyrimidinyl]- (CA INDEX NAME)



RN 1055985-13-1 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:343955 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 144:390936
TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases
INVENTOR(S): Patel, Vinod F.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harmange, Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.; Dimauro, Erin F.; Buchanan, John L.; McGowan, David C.; Albrecht, Brian K.; Deak, Holly L.; Bemis, Jean E.; White, Ryan; Martin, Matthew W.; Habgood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley J.; Graceffa, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzasa, Robert M.; Falsey, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang; Tomlinson, Susan Ann; Pettus, Liping H.; Smith, Adrian Leonard; Paras, Nick A.; Liu, Gang; Demorin, Frenel F.; Tasker, Andrew; Reed, Anthony

PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 876 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039718	A2	20060413	WO 2005-US35873	20051003 <--
WO 2006039718	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070054916	A1	20070308	US 2005-240590	20050930 <--
AU 2005292152	A1	20060413	AU 2005-292152	20051003 <--
CA 2582029	A1	20060413	CA 2005-2582029	20051003 <--
EP 1836174	A2	20070926	EP 2005-818381	20051003 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008515812	T	20080515	JP 2007-534914	20051003 <--
MX 2007003784	A	20070424	MX 2007-3784	20070329 <--
PRIORITY APPLN. INFO.:				
			US 2004-615535P	P 20041001 <--
			US 2005-240590	A 20050930
			WO 2005-US35873	W 20051003

OTHER SOURCE(S): CASREACT 144:390936; MARPAT 144:390936
IT 882674-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl nitrogen-containing bicyclic compds.
and
their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)
RN 882674-24-0 CAPLUS
CN 2-Quinazolinamine, N-methyl-6-[2-methyl-5-[[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L5 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696902 CAPLUS <<LOGINID::20091110>>


DOCUMENT NUMBER: 143:194003
TITLE: Preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders
INVENTOR(S): Herpin, Timothy F.; Morton, George C.; Reh fuss, Robert P.; Lawrence, R. Michael; Poss, Michael A.; Roberge, Jacques Y.; Gungor, Timur
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070920	A1	20050804	WO 2005-US1705	20050120 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050203146	A1	20050915	US 2005-38862	20050119 <--
US 7470712	B2	20081230		
EP 1706398	A1	20061004	EP 2005-711663	20050120 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
JP 2007518809	T	20070712	JP 2006-551237	20050120 <--
NO 2006003191	A	20061016	NO 2006-3191	20060710 <--
US 20080275090	A1	20081106	US 2008-104732	20080417 <--
PRIORITY APPLN. INFO.:			US 2004-537869P	P 20040121 <--
			US 2004-638167P	P 20041222
			US 2005-38862	A3 20050119
			WO 2005-US1705	W 20050120


OTHER SOURCE(S): CASREACT 143:194003; MARPAT 143:194003
IT 861670-93-1P 861670-94-2P,
N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-4-nitro-1H-benzo[d]imidazol-2-amine 861670-96-4P,
N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-nitro-1H-benzo[d]imidazol-2-amine 861671-18-3P,
N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-(1H-imidazol-1-yl)-7-methyl-1H-benzo[d]imidazol-2-amine 861671-20-7P,
4-Nitro-N-[2-[3-(trifluoromethyl)phenoxy]pyridin-3-yl]-1H-benzo[d]imidazol-2-amine 861671-22-9P, 5-Nitro-N-[2-[3-(trifluoromethyl)phenoxy]pyridin-3-yl]-1H-benzo[d]imidazol-2-amine 861671-92-3P, N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-5-methyl-3H-benzo[d]imidazole-2,4-diamine 861671-96-7P,
N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-6-(morpholino)-1H-benzo[d]imidazol-2-amine 861671-98-9P,
N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-N',N'-dimethyl-3H-benzo[d]imidazole-2,5-diamine 861674-50-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders)


RN 861670-93-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-5-(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)




RN 861670-94-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-7-nitro- (CA INDEX NAME)




RN 861670-96-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-6-nitro- (CA INDEX NAME)




RN 861671-18-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-5-(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)




RN 861671-20-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 7-nitro-N-[2-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 861671-22-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-nitro-N-[2-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 861671-92-3 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N2-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-6-methyl- (CA INDEX NAME)



RN 861671-96-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 861671-98-9 CAPLUS
 CN 1H-Benzimidazole-2,6-diamine, N2-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-N6,N6-dimethyl- (CA INDEX NAME)



RN 861674-50-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-

6-methyl-7-nitro- (CA INDEX NAME)




IT 1026562-20-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders)

RN 1026562-20-8 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-7-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:429393 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 142:482043

TITLE: Preparation of nitrogen-containing fused heterocyclic compounds like benzimidazoles and benzothiazoles as CRF receptor antagonists

INVENTOR(S): Gyorkos, Albert Charles; Corrette, Christopher Peter; Cho, Suk Young; Turner, Timothy Mark; Pratt, Scott Alan; Aso, Kazuyoshi; Kori, Masakuni; Gyoten, Michiyo

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044793	A2	20050519	WO 2004-US35648	20041027 <--
WO 2005044793	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2543707	A1	20050519	CA 2004-2543707	20041027 <--
EP 1677791	A2	20060712	EP 2004-810065	20041027 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007510646	T	20070426	JP 2006-538217	20041027 <--
US 20070135452	A1	20070614	US 2006-577334	20060428
PRIORITY APPLN. INFO.:			US 2003-516164P	P 20031031 <--
			US 2004-560518P	P 20040408 <--
			WO 2004-US35648	W 20041027


OTHER SOURCE(S): CASREACT 142:482043; MARPAT 142:482043

IT 851886-96-9P, N'-Benzyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851888-22-7P,
4-[[2-(4-Bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl](isopropyl)amino]butanoic acid 851888-23-8P, Methyl
4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](isopropyl)amino]butanoate 851888-51-2P, Ethyl
N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)glycinate 851888-76-1P,
5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenol 851889-02-6P, N-[2-(3-Bromopropoxy)-4-chlorophenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-03-7P,
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]butanenitrile 851889-08-2P,
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]butyric acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of nitrogen-containing fused heterocyclic compds.

like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)


RN 851886-96-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(phenylmethyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-22-7 CAPLUS

CN Butanoic acid, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]- (CA INDEX NAME)




RN 851888-23-8 CAPLUS

CN Butanoic acid, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-, methyl ester (CA INDEX NAME)




RN 851888-51-2 CAPLUS

CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 851888-76-1 CAPLUS

CN Phenol, 5-chloro-2-[[7-(diisopropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 851889-02-6 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-[2-(3-bromopropoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851889-03-7 CAPLUS

CN Butanenitrile, 4-[5-chloro-2-[[7-(diisopropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)



RN 851889-08-2 CAPLUS
CN Butanoic acid, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)



IT 851886-84-5P, N-Mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-87-8P, N-Mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-88-9P, 1-Isopropyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-89-0P, N-Mesityl-1-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-90-3P, 1-Ethyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-91-4P, N'-Cyclopropylmethyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851886-99-2P, 1-Methyl-N-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-03-1P, Methyl 4-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methylbenzoate trifluoroacetate 851887-05-3P, N-(2,6-Dimethoxypyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-07-5P, N-(4-tert-Butyl-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-09-7P, N-(2,4-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-11-1P, N-(4-Bromo-2-ethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-13-3P, N-[4-(Diethylamino)-2-methylphenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-15-5P, 1-Methyl-N-(4-methyl-5-nitropyridin-2-yl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-17-7P, N-(2,4-Dichlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-19-9P, N-(2-Chloro-4,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-21-3P, N-(2-Bromo-4-isopropylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-23-5P, 1-Methyl-N',N'-dipropyl-N-(2,4,6-trichlorophenyl)-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-27-9P, N-(4,5-Dimethoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-29-1P, N-(2,6-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-31-5P, 2,4-Dichloro-6-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methylphenol trifluoroacetate 851887-33-7P, N-(3,5-Dichloropyridin-4-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-35-9P, N-(3-Bromo-5-methylpyridin-2-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-37-1P, N-(3,5-Dimethoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-


diamine trifluoroacetate 851887-39-3P, 1-Methyl-N-[2-methyl-4-(trifluoromethoxy)phenyl]-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-41-7P, N-(2,4-Dimethoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-42-8P, N',N'-Dibutyl-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-43-9P, N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-44-0P, N-Mesityl-1-methyl-7-(piperidin-1-yl)-1H-benzimidazol-2-amine 851887-45-1P, N'-Butyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-46-2P, N-Mesityl-1-methyl-N'-(2-methoxyethyl)-N'-propyl-1H-benzimidazole-2,7-diamine 851887-47-3P, N'-Isobutyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-55-3P, 5-Fluoro-N-mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-57-5P, N',N'-Dibutyl-5-fluoro-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-58-6P, N',N'-Bis(cyclopropylmethyl)-5-fluoro-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-59-7P, N'-Butyl-N-mesityl-N'-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851887-63-3P, N-Mesityl-N'-methyl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-64-4P, N'-Isopropyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-65-5P, N-Mesityl-1-methyl-N'-(1-propylbutyl)-1H-benzimidazole-2,7-diamine 851887-66-6P, N'-Benzyl-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-67-7P, N'-(4-Chlorobenzyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-68-8P, N'-(Cyclopropylmethyl)-N-mesityl-N'-(4-methoxybenzyl)-1-methyl-1H-benzimidazole-2,7-diamine 851887-69-9P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-3-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-70-2P, N-(Cyclopropylmethyl)-N-[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]acetamide 851887-71-3P, N'-(4-tert-Butylbenzyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-72-4P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(4-methylbenzyl)-1H-benzimidazole-2,7-diamine 851887-73-5P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-4-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-74-6P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(4-(trifluoromethyl)benzyl)-1H-benzimidazole-2,7-diamine 851887-75-7P, N'-(Cyclopropylmethyl)-N'-(4-fluorobenzyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-76-8P, 4-[[{(Cyclopropylmethyl)[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]amino)methyl]benzonitrile 851887-77-9P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-2-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-78-0P, N'-[2-(Benzyloxy)ethyl]-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-79-1P, 2-[[{(Cyclopropylmethyl)[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]amino]ethanol 851887-80-4P, N-(4-Bromo-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-81-5P, N-(4-Methoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-82-6P, N-(2,6-Dimethoxy-4-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-83-7P, N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-84-8P, N-(2,6-Dichloropyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-85-9P, 4-[[7-(Dipropylamino)-1-methyl-1H-

benzimidazol-2-yl]amino]-3-ethylbenzonitrile 851887-86-0P,
N-(2,4-Dimethoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-
2,7-diamine hydrochloride 851887-87-1P,
N-(2,4-Dichloro-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-
2,7-diamine hydrochloride 851887-88-2P,
N-[2-Chloro-6-(trifluoromethyl)pyridin-3-yl]-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-89-3P,
N-[2-Chloro-4-(trifluoromethyl)phenyl]-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-90-6P,
N-(2-Bromo-4-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-91-7P,
N-(4-Chloro-2-methoxy-5-methylphenyl)-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-92-8P,
N-(4-Bromo-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-
diamine hydrochloride 851887-93-9P,
N'-(Cyclopropylmethyl)-N'-(2,4-dimethylbenzyl)-N-mesityl-1-methyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-94-0P,
N-(4-Bromo-2-ethylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-
diamine hydrochloride 851887-95-1P,
N-(4-Chloro-2-isopropyl-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-96-2P,
N',N'-Dibutyl-N-(2,4-dimethoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-
2,7-diamine hydrochloride 851887-97-3P,
N-(2-Bromo-4-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-
benzimidazole-2,7-diamine hydrochloride 851887-99-5P,
N-Mesityl-1-(2-methoxyethyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine
851888-00-1P, N-Mesityl-N',N'-dipropyl-1-(2,2,2-trifluoroethyl)-1H-
benzimidazole-2,7-diamine 851888-01-2P,
2-[7-(Dipropylamino)-2-(mesitylamino)-1H-benzimidazol-1-yl]ethanol
851888-02-3P, N',N'-Bis(cyclopropylmethyl)-1-methyl-N-(2,4,6-
trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-03-4P
, 1-Acetyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine
851888-04-5P, N',N'-Dibutyl-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-
benzimidazole-2,7-diamine 851888-05-6P,
N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-
benzimidazole-2,7-diamine 851888-06-7P,
4-Bromo-N-mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine
851888-12-5P, N-(2,4,6-Trimethylpyridin-3-yl)-1-methyl-N',N'-di-(2-
methoxyethyl)-1H-benzimidazole-2,7-diamine hydrochloride
851888-18-1P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-bis(2-
methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-20-5P
, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-(2-methoxyethyl)-N'-methyl-1-
methylbenzimidazole-2,7-diamine 851888-21-6P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-N'-(2-methoxyethyl)-1-
methyl-1H-benzimidazole-2,7-diamine 851888-24-9P,
4-[[2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-
yl](isopropyl)amino]-N-methylbutanamide 851888-25-0P,
4-[[2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-
yl](isopropyl)amino]-N,N-dimethylbutanamide 851888-26-1P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N'-(4-oxo-4-
(pyrrolidin-1-yl)butyl)-1H-benzimidazole-2,7-diamine
851888-27-2P, 4-[[2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-
methyl-1H-benzimidazol-7-yl](isopropyl)amino]-N,N-diethylbutanamide
851888-28-3P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(4-(morpholin-4-yl)-4-oxobutyl)-1H-benzimidazole-2,7-diamine
851888-29-4P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(4-oxo-4-(piperidin-1-yl)butyl)-1H-benzimidazole-2,7-diamine
851888-30-7P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(4-oxo-4-(4-thiomorpholinyl)butyl)-1H-benzimidazole-2,7-diamine
851888-31-8P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(4-(4-methylpiperazin-1-yl)-4-oxobutyl)-1H-benzimidazole-2,7-


diamine 851888-32-9P, N'-[2-[(4-Bromo-2-methoxy-6-
methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N'-isopropylglycinamide
851888-33-0P, N'-(2-Aminoethyl)-N-(4-bromo-2-methoxy-6-
methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine
Hydrochloride 851888-35-2P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-[2-(dimethylamino)ethyl]-N'-
isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride
851888-37-4P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-
chlorophenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine
Hydrochloride 851888-43-2P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-chlorophenyl)-1-methyl-N'-
neopentyl-1H-benzimidazole-2,7-diamine hydrochloride
851888-44-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-
chlorophenyl)-N'-(2-methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine
hydrochloride 851888-45-4P, Ethyl
N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-
yl]-N-(4-chlorophenyl)glycinate hydrochloride 851888-46-5P,
N'-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-
7-yl]-N'-(4-chlorophenyl)-N,N-dimethylglycinamide hydrochloride
851888-47-6P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-
chlorophenyl)-N'-[2-(dimethylamino)ethyl]-1-methyl-1H-benzimidazole-2,7-
diamine dihydrochloride 851888-48-7P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-chlorophenyl)-1-methyl-N'-
[(tetrahydrofuran-3-yl)methyl]-1H-benzimidazole-2,7-diamine
851888-49-8P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-
N'-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine
851888-50-1P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(2-
methoxyethyl)-N'-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine
851888-52-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(4-
methoxyphenyl)-1-methyl-N'-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-
benzimidazole-2,7-diamine 851888-53-4P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N'-(5-
methylpyridin-2-yl)-1H-benzimidazole-2,7-diamine 851888-54-5P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-(2-methoxyethyl)-1-methyl-N'-(5-
methylpyridin-2-yl)-1H-benzimidazole-2,7-diamine 851888-55-6P,
N'-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-
7-yl]-N,N-diethyl-N'-(4-methoxyphenyl)glycinamide Hydrochloride
851888-56-7P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-
methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)acetamide Hydrochloride
851888-58-9P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-
methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide
851888-59-0P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(4-(methylsulfonyl)phenyl)-1H-benzimidazole-2,7-diamine
851888-61-4P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-
methyl-N'-(3-(methylsulfonyl)phenyl)-1H-benzimidazole-2,7-diamine
851888-62-5P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-ethyl-N'-
isopropyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride
851888-63-6P, N-(4-Bromo-2,6-diethylphenyl)-1-methyl-N',N'-
dipropyl-1H-benzimidazole-2,7-diamine 851888-64-7P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-
benzimidazole-2,7-diamine 851888-65-8P,
N-(4-Chloro-2,6-diethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-
2,7-diamine 851888-66-9P, Methyl
4-[(cyclopropylmethyl)[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-
yl]amino]butanoate 851888-67-0P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-
benzimidazole-2,7-diamine 851888-68-1P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine 851888-69-2P,
N-(3,4-Dichloro-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-
benzimidazole-2,7-diamine 851888-70-5P,

N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-N'-methyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-71-6P,
N'-Ethyl-N'-isopropyl-1-methyl-N-(2,4,6-trimethoxyphenyl)-1H-benzimidazole-2,7-diamine 851888-72-7P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-73-8P,
N-(4-Chloro-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-74-9P,
N-(4-Chloro-2,6-diethylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-75-0P, N-(4-Chloro-2,6-diethylphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-77-2P,
[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenyl]methanol 851888-78-3P,
N-(4-Chloro-2-methoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-79-4P, N-(2-Bromo-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-81-8P,
5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]benzonitrile 851888-82-9P,
N-(4-Chloro-2-(methoxymethyl)phenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-83-0P,
N',N'-Bis[2-(benzyloxy)ethyl]-1-methyl-N-(2,4,6-trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-84-1P,
N-(4-Chloro-2-ethoxyphenyl)-3-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-85-2P, 1-Methyl-N-(pentamethylphenyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-86-3P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-amine 851888-89-6P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methylpiperidin-1-yl)-1H-benzimidazol-2-amine 851888-90-9P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidinyl)-1-methyl-1H-benzimidazol-2-amine 851888-91-0P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1H-pyrrolidin-1-yl)-1H-benzimidazol-2-amine 851888-92-1P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl-1H-benzimidazol-2-amine 851888-93-2P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-94-3P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-95-4P,
N-[7-(2-Ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-yl]-N,N-dimethyl-4-methyl-2,5-pyridinediamine 851888-96-5P, Methyl 1-[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]piperidine-2-carboxylate 851889-04-8P,
N-[2-(2-Bromoethoxy)-4-chlorophenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-05-9P,
[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]acetonitrile 851889-06-0P,
N-[2-(4-Bromobutoxy)-4-chlorophenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-07-1P,
5-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]pentanenitrile 851889-09-3P,
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N-methylbutanamide Hydrochloride 851889-10-6P,
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N,N-dimethylbutanamide 851889-19-5P,
N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-propyl-1-methyl-N'-[2-(methylsulfonyl)phenyl]-1H-benzimidazole-2,7-diamine 851889-22-0P, 4-[[2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl] (isopropyl)amino]benzonitrile 851889-28-6P, 4-[[2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl] (isopropyl)amino]-2-methoxybenzonitrile


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of nitrogen-containing fused heterocyclic compds.
like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)
RN 851886-84-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-87-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-88-9 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-(1-methylethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-89-0 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-90-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-ethyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-91-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-99-2 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-phenyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851886-98-1


CMF C20 H26 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851887-03-1 CAPLUS

CN Benzoic acid, 4-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methyl-, methyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-02-0


CMF C23 H30 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 851887-05-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-3-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-04-2
CMF C21 H29 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-07-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-06-4
CMF C26 H38 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-09-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-08-6
CMF C22 H30 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-11-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-10-0
CMF C22 H29 Br N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-13-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-[4-(diethylamino)-2-methylphenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-12-2
CMF C25 H37 N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-15-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(4-methyl-5-nitro-2-pyridinyl)-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-14-4
CMF C20 H26 N6 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-17-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichlorophenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-16-6
CMF C20 H24 Cl2 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-19-9 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-chloro-4,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-18-8
 CMF C22 H29 Cl N4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 851887-21-3 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N2-[2-bromo-4-(1-methylethyl)phenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-20-2
 CMF C23 H31 Br N4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 851887-23-5 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-dipropyl-N2-(2,4,6-trichlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-22-4
 CMF C20 H23 Cl3 N4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 851887-27-9 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4,5-dimethoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-26-8
CMF C23 H32 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-29-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-28-0
CMF C22 H30 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-31-5 CAPLUS
CN Phenol, 2,4-dichloro-6-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-30-4
CMF C21 H26 Cl2 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-33-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dichloro-4-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-32-6
CMF C19 H23 Cl2 N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-35-9 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(3-bromo-5-methyl-2-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-34-8
CMF C20 H26 Br N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-37-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dimethoxyphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-36-0
CMF C22 H30 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-39-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-[2-methyl-4-(trifluoromethoxy)phenyl]-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-38-2
CMF C22 H27 F3 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 851887-41-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxyphenyl)-1-methyl-N7, N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 851887-40-6
CMF C22 H30 N4 O2




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 851887-42-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-43-9 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-44-0 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-methyl-7-(1-piperidinyl)-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-45-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-46-2 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-(2-methoxyethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-47-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(2-methylpropyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-55-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 5-fluoro-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-57-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-58-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 851887-59-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-N7-(4-methoxyphenyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-63-3 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N7,1-dimethyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-64-4 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-methylethyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-65-5 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-propylbutyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-66-6 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(phenylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-67-7 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N7-[(4-chlorophenyl)methyl]-N7-(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-68-8 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-methoxyphenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-69-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(3-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-70-2 CAPLUS

CN Acetamide, N-(cyclopropylmethyl)-N-[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]- (CA INDEX NAME)




RN 851887-71-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-72-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[(4-methylphenyl)methyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-73-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(4-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-74-6 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[[4-(trifluoromethyl)phenyl]methyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-75-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-fluorophenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-76-8 CAPLUS
CN Benzonitrile, 4-[[{(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]methyl]- (CA INDEX NAME)




RN 851887-77-9 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(2-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-78-0 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[2-(phenylmethoxy)ethyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-79-1 CAPLUS
CN Ethanol, 2-[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]- (CA INDEX NAME)




RN 851887-80-4 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-81-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-methoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-82-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-4-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-83-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-84-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dichloro-3-pyridinyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851887-85-9 CAPLUS
CN Benzonitrile, 4-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-ethyl- (CA INDEX NAME)




RN 851887-86-0 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-87-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichloro-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-88-2 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-[2-chloro-6-(trifluoromethyl)-3-pyridinyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-89-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-[2-chloro-4-(trifluoromethyl)phenyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-90-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-91-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-5-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 851887-92-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 851887-93-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(2,4-dimethylphenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-94-0 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-95-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-[4-chloro-2-methyl-6-(1-methylethyl)phenyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-96-2 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-97-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl


RN 851887-99-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 1-(2-methoxyethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-00-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-01-2 CAPLUS
CN 1H-Benzimidazole-1-ethanol, 7-(dipropylamino)-2-[(2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)




RN 851888-02-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-03-4 CAPLUS
CN Ethanone, 1-[7-(dipropylamino)-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 851888-04-5 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851888-05-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-06-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, 4-bromo-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851888-12-5 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(2-methoxyethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 851888-18-1 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-bis(2-methoxyethyl)-1-methyl- (CA INDEX NAME)




RN 851888-20-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-N7,1-dimethyl- (CA INDEX NAME)




RN 851888-21-6 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-24-9 CAPLUS

CN Butanamide, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-N-methyl- (CA INDEX NAME)




RN 851888-25-0 CAPLUS

CN Butanamide, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 851888-26-1 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 851888-27-2 CAPLUS

CN Butanamide, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-N,N-diethyl- (CA INDEX NAME)




RN 851888-28-3 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 851888-29-4 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(1-piperidyl)- (CA INDEX NAME)




RN 851888-30-7 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 851888-31-8 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 851888-32-9 CAPLUS

CN Acetamide, 2-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]- (CA INDEX NAME)



RN 851888-33-0 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851888-35-2 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-[2-(dimethylamino)ethyl]-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 851888-37-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-43-2 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-(2,2-dimethylpropyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-44-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-(2-methoxyethyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-45-4 CAPLUS
CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 851888-46-5 CAPLUS
CN Acetamide, 2-[[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](4-chlorophenyl)amino]-N,N-dimethyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851888-47-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-[2-(dimethylamino)ethyl]-1-methyl-, hydrochloride (1:2)
(CA INDEX NAME)




●2 HCl


RN 851888-48-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-[(tetrahydro-3-furanyl)methyl]- (CA INDEX NAME)



RN 851888-49-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-methoxyphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-50-1 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-N7-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)




RN 851888-52-3 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-

methoxyphenyl)-1-methyl-N7-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 851888-53-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 851888-54-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-1-methyl-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 851888-55-6 CAPLUS


CN Acetamide, 2-[[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl] (4-methoxyphenyl)amino]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851888-56-7 CAPLUS


CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851888-58-9 CAPLUS


CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 851888-59-0 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 851888-61-4 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 851888-62-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 851888-63-6 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-diethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851888-64-7 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,N7-dibutyl-1-methyl- (CA INDEX NAME)




RN 851888-65-8 CAPLUS
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-66-9 CAPLUS

CN Butanoic acid, 4-[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]-, methyl ester (CA INDEX NAME)




RN 851888-67-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-68-1 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-69-2 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(3,4-dichloro-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-70-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,1-dimethyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-71-6 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-ethyl-1-methyl-N7-(1-methylethyl)-N2-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 851888-72-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-73-8 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-74-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-75-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-77-2 CAPLUS

CN Benzenemethanol, 5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 851888-78-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxyphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-79-4 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-chlorophenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-81-8 CAPLUS
 CN Benzonitrile, 5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 851888-82-9 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, N2-[4-chloro-2-(methoxymethyl)phenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-83-0 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-bis[2-(phenylmethoxy)ethyl]-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-84-1 CAPLUS
 CN 1H-Benzimidazole-2,4-diamine, N2-(4-chloro-2-ethoxyphenyl)-2,3-dihydro-1-methyl-N4,N4-dipropyl- (CA INDEX NAME)




RN 851888-85-2 CAPLUS
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,3,4,5,6-pentamethylphenyl)-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-86-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl- (CA INDEX NAME)




RN 851888-89-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 851888-90-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidinyl)-1-methyl- (CA INDEX NAME)




RN 851888-91-0 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-pyrrolidinyl)- (CA INDEX NAME)




RN 851888-92-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl- (CA INDEX NAME)




RN 851888-93-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidinyl)- (CA INDEX NAME)




RN 851888-94-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-[2-(methoxymethyl)-1-piperidinyl]-1-methyl- (CA INDEX NAME)



RN 851888-95-4 CAPLUS
 CN 2,5-Pyridinediamine, N5-[7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-yl]-N2,N2,4-trimethyl- (CA INDEX NAME)




RN 851888-96-5 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-, methyl ester (CA INDEX NAME)




RN 851889-04-8 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-[2-(2-bromoethoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851889-05-9 CAPLUS

CN Acetonitrile, 2-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)




RN 851889-06-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-[2-(4-bromobutoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851889-07-1 CAPLUS

CN Pentanenitrile, 5-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)



RN 851889-09-3 CAPLUS


CN Butanamide, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N-methyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 851889-10-6 CAPLUS

CN Butanamide, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 851889-19-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-[2-(methylsulfonyl)phenyl]-N7-propyl- (CA INDEX NAME)




RN 851889-22-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]- (CA INDEX NAME)



RN 851889-28-6 CAPLUS

CN Benzonitrile, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-2-methoxy- (CA INDEX NAME)



IT 851888-19-2, N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-34-1, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-


benzimidazole-2,7-diamine 851888-36-3, N'-(2-Aminoethyl)-N-(4-bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)


RN 851888-19-2 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl- (CA INDEX NAME)




RN 851888-34-1 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)



RN 851888-36-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)



IT 851886-86-7P, N-Mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851886-97-0P, N-Mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)


RN 851886-86-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-97-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:409508 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 142:463726

TITLE: Preparation of benzimidazolyls as TIE-2 tyrosine kinase inhibitors for the treatment of tumors

INVENTOR(S): Staehle, Wolfgang; Buchstaller, Hans-Peter; Jonczyk, Alfred; Rautenberg, Wilfried

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042520	A1	20050512	WO 2004-EPI1550	20041014 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10349587	A1	20050525	DE 2003-10349587	20031024 <--
AU 2004285643	A1	20050512	AU 2004-285643	20041014 <--
CA 2543346	A1	20050512	CA 2004-2543346	20041014 <--
EP 1675849	A1	20060705	EP 2004-765962	20041014 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1871232	A	20061129	CN 2004-80031334	20041014 <--
BR 2004015760	A	20061219	BR 2004-15760	20041014 <--
JP 2007509096	T	20070412	JP 2006-536006	20041014 <--
MX 2006004405	A	20060614	MX 2006-4405	20060420 <--
KR 2006123124	A	20061201	KR 2006-707939	20060424 <--
US 20070066660	A1	20070322	US 2006-577033	20060424 <--
US 7470702	B2	20081230		
IN 2006KN01239	A	20070427	IN 2006-KN1239	20060511 <--
ZA 2006004148	A	20070926	ZA 2006-4148	20060523 <--
US 20090082404	A1	20090326	US 2008-328320	20081204 <--
PRIORITY APPLN. INFO.:				
			DE 2003-10349587	A 20031024 <--
			WO 2004-EPI1550	W 20041014 <--
			US 2006-577033	A3 20060424

OTHER SOURCE(S): MARPAT 142:463726


IT 851677-44-6P, (6-Nitro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine 851677-52-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolyls as TIE-2 tyrosine kinase inhibitors for treatment of tumors)


RN 851677-44-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-nitro-N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 851677-52-6 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:76237 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 142:176860

TITLE: Preparation of thienopyrimidine derivatives as ErbB
kinase inhibitors

INVENTOR(S): Dickerson, Scott Howard; Emerson, Holly Kathleen;
Hinkle, Kevin Wayne; Hornberger, Keith Robert;
Sammond, Douglas McCord; Smith, Stephen; Stevens, Kirk
Lawrence; Hubbard, Robert Dale; Petrov, Kimberly
Glennon; Reno, Michael John; Uehling, David Edward;
Waterson, Alex Gregory

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 241 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007083	A2	20050127	WO 2004-US19410	20040617 <--
WO 2005007083	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-479324P P 20030618 <--

OTHER SOURCE(S): CASREACT 142:176860; MARPAT 142:176860


IT 833475-75-5P, N-(4-Fluorophenyl)-N'-[6-[(2R)-2-
pyrrolidinylethynyl]thieno[3,2-d]pyrimidin-4-yl]-1H-benzimidazole-2,5-
diamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of thienopyrimidines as ErbB kinase inhibitors)

RN 833475-75-5 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-(4-fluorophenyl)-N6-[6-[2-(2R)-2-
pyrrolidinylethynyl]thieno[3,2-d]pyrimidin-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:14275 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 142:114106

TITLE: Preparation of heterocyclic compounds for preventing
and treating disorders associated with excessive bone
loss

INVENTOR(S): Ono, Mitsunori; Sun, Lijun; Wada, Yumiko; Koya, Keizo;
Nagai, Masazumi

PATENT ASSIGNEE(S): Synta Pharmaceuticals, Corp., USA

SOURCE: PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000404	A2	20050106	WO 2004-US17064	20040528 <--
WO 2005000404	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004251641	A1	20050106	AU 2004-251641	20040528 <--
CA 2527079	A1	20050106	CA 2004-2527079	20040528 <--
EP 1626725	A2	20060222	EP 2004-776190	20040528 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007500241 T 20070111 JP 2006-533518 20040528 <--
US 20080058297 A1 20080306 US 2006-561025 20060519 <--
PRIORITY APPLN. INFO.: US 2003-474410P P 20030529 <--
US 2003-474502P P 20030529 <--
US 2003-474550P P 20030529 <--
WO 2004-US17064 W 20040528 <--

OTHER SOURCE(S): MARPAT 142:114106


IT 682337-78-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidines, triazines and purines for preventing and
treating disorders associated with excessive bone loss)

RN 682337-78-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl-
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:817883 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 141:332190

TITLE: Preparation of fused azoles such as 2,5-disubstituted
benzimidazoles, benzoxazoles and benzothiazoles as
kinase inhibitors

INVENTOR(S): Dipietro, Lucian V.; Harmange, Jean-Christophe; Askew,
Benny C., Jr.; Elbaum, Daniel; Germain, Julie;
Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.;
Potashman, Michele; Van der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 289 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085425	A1	20041007	WO 2004-US8809	20040322 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 7531553	B2	20090512	US 2004-804915	20040319 <--
US 20040209892	A1	20041021		
AU 2004223827	A1	20041007	AU 2004-223827	20040322 <--
AU 2004223827	B2	20080306		
CA 2518909	A1	20041007	CA 2004-2518909	20040322 <--
EP 1638954	A1	20060329	EP 2004-758050	20040322 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

JP 2006520805	T	20060914	JP 2006-507472	20040322 <--
MX 2005010086	A	20060210	MX 2005-10086	20050921 <--

PRIORITY APPLN. INFO.: US 2003-456691P P 20030321 <--
US 2004-804915 A 20040319 <--
WO 2004-US8809 A 20040322 <--

OTHER SOURCE(S): MARPAT 141:332190

IT 1055984-37-6P 1055984-58-1P 1055984-62-7P


1055985-13-1P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as
kinase inhibitors)


RN 1055984-37-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-
yl]amino]-N-methyl- (CA INDEX NAME)




RN 1055984-58-1 CAPLUS


CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-
quinolinyl)- (CA INDEX NAME)



RN 1055984-62-7 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-[2-(methylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1055985-13-1 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:513393 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 141:71544
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors
INVENTOR(S): Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040122237	A1	20040624	US 2003-675927	20030929 <--
US 20040087626	A1	20040506	US 2003-405945	20030331 <--
US 7071216	B2	20060704		

AU 2004277405 A1 20050414 AU 2004-277405 20040929 <--
CA 2539748 A1 20050414 CA 2004-2539748 20040929 <--
WO 2005032548 A1 20050414 WO 2004-US32161 20040929 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1675584 A1 20060705 EP 2004-789345 20040929 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
BR 2004014908 A 20061107 BR 2004-14908 20040929 <--
CN 1913884 A 20070214 CN 2004-80032677 20040929 <--
JP 2007507428 T 20070329 JP 2006-528331 20040929 <--
US 20070299039 A1 20071227 US 2005-282939 20051118 <--
MX 2006003435 A 20060620 MX 2006-3435 20060327 <--
JP 2006193533 A 20060727 JP 2006-96143 20060330 <--
KR 2006089232 A 20060808 KR 2006-706470 20060403 <--
IN 2006KN00838 A 20070413 IN 2006-KN838 20060405 <--
ZA 2006003418 A 20070725 ZA 2006-3418 20060428 <--
PRIORITY APPLN. INFO.: US 2002-369066P P 20020329 <--
US 2003-405945 A2 20030331 <--
JP 2003-579810 A3 20030331 <--
US 2003-675927 A 20030929 <--
WO 2004-US32161 W 20040929 <--


OTHER SOURCE(S): MARPAT 141:71544

IT 611220-17-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611220-17-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]amino]-N-methyl- (CA INDEX NAME)



IT 611225-93-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)
RN 611225-93-5 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(19 CITINGS)

L5 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:355045 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 140:357119
TITLE: Preparation of amino morpholinopurine derivatives for
treating interleukin-12 overproduction-related
disorders
INVENTOR(S): Sun, Lijun; Ono, Mitsunori; Wada, Yumiko; Ying,
Weiwen; Przewloka, Teresa; Kostik, Elena
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035740	A2	20040429	WO 2003-US32546	20031014 <--
WO 2004035740	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2502356 A1 20040429 CA 2003-2502356 20031014 <-- AU 2003284142 A1 20040504 AU 2003-284142 20031014 <-- US 20040198725 A1 20041007 US 2003-686505 20031014 <-- US 7122665 B2 20061017 EP 1556140 A2 20050727 EP 2003-776373 20031014 <-- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK JP 2006507273 T 20060302 JP 2004-545265 20031014 <-- US 20070027151 A1 20070201 US 2006-542963 20061003 <-- US 7410990 B2 20080812 PRIORITY APPLN. INFO.: US 2002-418984P P 20021015 <-- US 2003-686505 A1 20031014 <-- WO 2003-US32546 W 20031014 <--				

OTHER SOURCE(S): MARPAT 140:357119
IT 682337-78-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)
(preparation of amino morpholinopurine derivs. for treating interleukin-12
overprodn.-related disorders)

RN 682337-78-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:6498 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 141:136262
TITLE: Molecular Modeling and Design of Radiolabelled
Complexes for Melanoma Diagnosis
AUTHOR(S): Tuttle, C. T. Tell; Seabrook, Shane A.; Wise, Lauren
E.; Katsifis, Andrew; Knott, Robert B.; Yates, Brian
F.
CORPORATE SOURCE: School of Chemistry, University of Tasmania, Hobart,
TAS 7001, Australia
SOURCE: Australian Journal of Chemistry (2004),
57(1), 87-96
CODEN: AJCHAS; ISSN: 0004-9425
PUBLISHER: CSIRO Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 727408-66-4
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(integrin receptor-binding)
RN 727408-66-4 CAPLUS
CN L-Alanine, 3-[[[7-nitro-2-(phenylamino)-1H-benzimidazol-5-
yl]carbonyl]amino]-N-(phenylsulfonyl)- (CA INDEX NAME)
Absolute stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796477 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 139:307759
TITLE: Preparation of substituted benzazoles as Raf kinase
inhibitors
INVENTOR(S): Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman;
Levine, Barry Haskell; Poon, Daniel J.; Subramanian,
Sharadha; Sung, Leonard; Fantl, Wendy
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082272	A1	20031009	WO 2003-US10117	20030331 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480638	A1	20031009	CA 2003-2480638	20030331 <--
AU 2003226211	A1	20031013	AU 2003-226211	20030331 <--
AU 2003226211	B2	20080529		
EP 1499311	A1	20050126	EP 2003-745683	20030331 <--
EP 1499311	B1	20091104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008854	A	20050222	BR 2003-8854	20030331 <--
CN 1655779	A	20050817	CN 2003-812193	20030331 <--
CN 100515419	C	20090722		
JP 2005529089	T	20050929	JP 2003-579810	20030331 <--
NZ 535985	A	20070427	NZ 2003-535985	20030331 <--
AP 1913	A	20081031	AP 2004-3161	20030331 <--
IN 2004KN01433	A	20051230	IN 2004-KN1433	20040927 <--
MX 2004009541	A	20050125	MX 2004-9541	20040929 <--

NO 2004004617 A 20041228 NO 2004-4617 20041026 <--
ZA 2004008386 A 20060531 ZA 2004-8386 20060308 <--
JP 2006193533 A 20060727 JP 2006-96143 20060330 <--
PRIORITY APPLN. INFO.: US 2002-369066P P 20020329 <--
JP 2003-579810 A3 20030331 <--
WO 2003-US10117 W 20030331 <--

OTHER SOURCE(S): MARPAT 139:307759
IT 611220-17-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors)
RN 611220-17-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-
yl]amino]-N-methyl- (CA INDEX NAME)



IT 611225-93-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted benzazoles as Raf kinase inhibitors)
RN 611225-93-5 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS
RECORD (22 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:719473 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 139:246042
TITLE: Preparation of benzimidazolylamino arylamino
pyrimidine TIE-2 and/or VEGFR inhibitors and their use
as angiogenesis inhibitors
INVENTOR(S): Chamberlain, Stanley Dawes; Cheung, Mui; Emerson,
Holly Kathleen; Johnson, Neil W.; Nailor, Kristen
Elizabeth; Sammond, Douglas Mccord; Semones, Marcus
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 253 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074515	A1	20030912	WO 2003-US6022	20030228 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GE, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477505	A1	20030912	CA 2003-2477505	20030228 <--
AU 2003220970	A1	20030916	AU 2003-220970	20030228 <--
EP 1487824	A1	20041222	EP 2003-743709	20030228 <--
EP 1487824	B1	20070620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005524668	T	20050818	JP 2003-572983	20030228 <--
AT 365165	T	20070715	AT 2003-743709	20030228 <--
ES 2290479	T3	20080216	ES 2003-743709	20030228 <--
MX 2004008458	A	20041206	MX 2004-8458	20040901 <--
US 20050234083	A1	20051020	US 2004-506447	20040901 <--
US 7338959	B2	20080304		
PRIORITY APPLN. INFO.:		US 2002-360741P P 20020301 <-- WO 2003-US6022 W 20030228 <--		


OTHER SOURCE(S): MARPAT 139:246042

IT 596132-35-3P, [1-Methyl-5-[methyl[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]phenylcarbamic acid tert-butyl ester hydrochloride
596132-38-6P, [1-Methyl-5-[methyl[2-[(4-methyl-3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]phenylcarbamic acid tert-butyl ester hydrochloride
596132-67-1P, [5-[[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl](methyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)carbamic acid tert-butyl ester 596132-70-6P, (4-Methoxyphenyl)[1-methyl-5-[methyl[2-[(4-sulfamoylmethylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester 596132-73-9P, [5-[[2-[[3-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl](methyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)carbamic acid tert-butyl ester 596132-76-2P, [5-[[2-[[4-[(1-Methanesulfonyl)ethyl]phenyl]amino]pyrimidin-4-yl](methyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)carbamic acid tert-butyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)
RN 596132-35-3 CAPLUS
CN Carbamic acid, [5-[[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 596132-38-6 CAPLUS
CN Carbamic acid, [5-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 596132-67-1 CAPLUS
CN Carbamic acid, (4-methoxyphenyl)[1-methyl-5-[methyl[2-[[4-[(methanesulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596132-70-6 CAPLUS
CN Carbamic acid, [5-[[2-[[4-[(aminosulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596132-73-9 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)[1-methyl-5-[methyl[2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596132-76-2 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)[1-methyl-5-[methyl[2-[[4-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 596131-79-2P, N'-Methyl-1-methyl-N'-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N-phenyl-1H-benzimidazole-2,5-diamine 596131-80-5P 596132-36-4P, 3-[[4-[Methyl (1-methyl-2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide 596132-37-5P, 3-[[4-[Methyl (1-methyl-2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide trifluoroacetate 596132-39-7P, N'-[2-[[3-(Methanesulfonyl)-4-methylphenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N-phenyl-1H-benzimidazole-2,5-diamine 596132-40-0P 596132-41-1P, 1-[4-[[4-[Methyl (1-methyl-2-phenylamino-1H-

benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide 596132-42-2P, [4-[[4-[Methyl (1-methyl-2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide trifluoroacetate 596132-43-3P, Methanesulfonic acid 4-[[4-[methyl (1-methyl-2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]phenyl ester 596132-44-4P, Methanesulfonic acid 4-[[4-[methyl (1-methyl-2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 596132-45-5P, 3-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide 596132-46-6P, 3-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide trifluoroacetate 596132-47-7P, 5-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide 596132-48-8P, 5-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide trifluoroacetate 596132-49-9P, N-(4-Fluorophenyl)-N'-[2-[[4-[(methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596132-50-2P 596132-51-3P, 1-[4-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide 596132-52-4P, [4-[[4-[[2-[[4-(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide trifluoroacetate 596132-53-5P, Methanesulfonic acid 4-[[4-[[2-[[4-(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl ester 596132-54-6P, Methanesulfonic acid 4-[[4-[[2-[[4-(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 596132-55-7P, Methanesulfonic acid 3-[[4-[[2-[[4-(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl ester 596132-56-8P, Methanesulfonic acid 3-[[4-[[2-[[4-(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 596132-58-0P, N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N-p-tolyl-1H-benzimidazole-2,5-diamine 596132-59-1P 596132-60-4P, 1-[4-[[4-[[2-[[4-(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide 596132-61-5P, [4-[[4-[[2-[[4-(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide trifluoroacetate 596132-62-6P, 3-[[4-[[2-[[4-(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide 596132-63-7P, 3-[[4-[[2-[[4-(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide trifluoroacetate 596132-64-8P, 5-[[4-[[2-[[4-(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl] (methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide hydrochloride 596132-65-9P, N-(4-tert-Butylphenyl)-N'-[2-[[4-[(methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596132-66-0P 596132-69-3P 596132-74-0P, N'-[2-[[3-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596132-75-1P 596132-77-3P, N'-[2-[[4-[1-(Methanesulfonyl)ethyl]phenyl]amino]pyrimidin-4-yl]-N-(4-

methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine
 596132-78-4P 596132-79-5P,
 N'-[2-[[3-[1-(Methanesulfonyl)ethyl]phenyl]amino]pyrimidin-4-yl]-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine
 596132-80-8P 596133-05-0P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine
 596133-06-1P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(3-chlorophenyl)-1H-benzimidazole-2,5-diamine 596133-07-2P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-chlorophenyl)-1H-benzimidazole-2,5-diamine
 596133-08-3P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,4-dichlorophenyl)-1H-benzimidazole-2,5-diamine 596133-09-4P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,5-dichlorophenyl)-1H-benzimidazole-2,5-diamine
 596133-10-7P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine
 596133-11-8P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-5-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine
 596133-12-9P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-morpholinophenyl)-1H-benzimidazole-2,5-diamine 596133-13-0P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(3-fluorophenyl)-1H-benzimidazole-2,5-diamine
 596133-14-1P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,4-difluorophenyl)-1H-benzimidazole-2,5-diamine 596133-15-2P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-fluorophenyl)-1H-benzimidazole-2,5-diamine
 596133-16-3P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-chloro-2-fluorophenyl)-1H-benzimidazole-2,5-diamine 596133-17-4P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-5-fluorophenyl)-1H-benzimidazole-2,5-diamine
 596133-18-5P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluoro-4-methylphenyl)-1H-benzimidazole-2,5-diamine 596133-20-9P,
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluorophenyl)-1H-benzimidazole-2,5-diamine
 596133-21-0P, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluoro-5-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine
 596133-26-5P, 4-[[4-[Methyl[1-methyl-2-[(4-trifluoromethylphenyl)amino]-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide 596133-35-6P,
 N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N-(3-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine
 596135-00-1P, Phenyl[1-Methyl-5-[methyl[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester 596135-01-2P,
 (Phenyl)[1-Methyl-5-[methyl[2-[(4-methyl-3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester
 596135-02-3P, 5-[[4-[[2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl](methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


{Uses}
 (drug candidate; preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)

RN 596131-79-2 CAPLUS
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-phenyl- (CA INDEX NAME)




RN 596131-80-5 CAPLUS
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1
 CRN 596131-79-2
 CMF C27 H27 N7 O2 S



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 596132-36-4 CAPLUS
 CN Benzenesulfonamide, 3-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-37-5 CAPLUS
CN Benzenesulfonamide, 3-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}


CM 1

CRN 596132-36-4
CMF C25 H24 N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-39-7 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-methyl-3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]-N2-phenyl- {CA INDEX NAME}



RN 596132-40-0 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-methyl-3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]-N2-phenyl-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}


CM 1

CRN 596132-39-7
CMF C27 H27 N7 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-41-1 CAPLUS
CN Benzenemethanesulfonamide, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- {CA INDEX NAME}



RN 596132-42-2 CAPLUS
CN Benzenemethanesulfonamide, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}


CM 1

CRN 596132-41-1
CMF C26 H26 N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-43-3 CAPLUS
CN Phenol, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-44-4 CAPLUS
CN Phenol, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-43-3
CMF C26 H25 N7 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-45-5 CAPLUS
CN Benzenesulfonamide, 3-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-46-6 CAPLUS
CN Benzenesulfonamide, 3-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-45-5
CMF C25 H23 F N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-47-7 CAPLUS
CN Benzenesulfonamide, 5-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)



RN 596132-48-8 CAPLUS
CN Benzenesulfonamide, 5-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-47-7
CMF C26 H25 F N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-49-9 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-50-2 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-49-9
CMF C27 H26 F N7 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-51-3 CAPLUS
 CN Benzenemethanesulfonamide, 4-[[[4-[[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-52-4 CAPLUS
 CN Benzenemethanesulfonamide, 4-[[[4-[[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-51-3
 CMF C26 H25 F N8 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596132-53-5 CAPLUS
 CN Phenol, 4-[[[4-[[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-54-6 CAPLUS
 CN Phenol, 4-[[[4-[[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-53-5
 CMF C26 H24 F N7 O3 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 596132-55-7 CAPLUS
 CN Phenol, 3-[[[4-[[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-56-8 CAPLUS
CN Phenol, 3-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}


CM 1

CRN 596132-55-7
CMF C26 H24 F N7 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-58-0 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-[2-[[4-(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-59-1 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-[2-[[4-(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}


CM 1

CRN 596132-58-0
CMF C28 H29 N7 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 596132-60-4 CAPLUS
CN Benzenemethanesulfonamide, 4-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 596132-61-5 CAPLUS
CN Benzenemethanesulfonamide, 4-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CRN 596132-60-4


CMF C30 H34 N8 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 596132-62-6 CAPLUS

CN Benzenesulfonamide, 3-[[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl-, (CA INDEX NAME)




RN 596132-63-7 CAPLUS

CN Benzenesulfonamide, 3-[[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-62-6


CMF C29 H32 N8 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 596132-64-8 CAPLUS


CN Benzenesulfonamide, 5-[[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 596132-65-9 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-[4-(1,1-dimethylethyl)phenyl]-N5,1-dimethyl-N5-[2-[[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-(CA INDEX NAME)




RN 596132-66-0 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-[4-(1,1-dimethylethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CRN 596132-65-9


CMF C31 H35 N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 596132-69-3 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CRN 596132-68-2


CMF C28 H29 N7 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 596132-74-0 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596132-75-1 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1


CRN 596132-74-0

CMF C28 H29 N7 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-77-3 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-78-4 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-77-3
CMF C29 H31 N7 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 596132-79-5 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-80-8 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 596132-79-5
CMF C29 H31 N7 O3 S




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 596133-05-0 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-06-1 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(3-chlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-07-2 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-chlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-08-3 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2,4-dichlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-09-4 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2,5-dichlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-10-7 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-[2-chloro-4-(trifluoromethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-11-8 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-5-(trifluoromethyl)phenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-12-9 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-(4-(4-morpholinyl)phenyl)- (CA INDEX NAME)




RN 596133-13-0 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(3-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-14-1 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2,4-difluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-15-2 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-16-3 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(4-chloro-2-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-17-4 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-5-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-18-5 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluoro-4-methylphenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-20-9 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-21-0 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N2-[2-fluoro-5-(trifluoromethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596133-26-5 CAPLUS
CN Benzenesulfonamide, 4-[[4-[methyl[1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 596133-35-6 CAPLUS
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596135-00-1 CAPLUS

CN Carbamic acid, [5-[[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596135-01-2 CAPLUS

CN Carbamic acid, [5-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596135-02-3 CAPLUS

CN Benzenesulfonamide, 5-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




IT 596130-89-1P, tert-Butyl

[5-[[2-chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl]phenylcarbamate 596130-90-4P,
1-Methyl-5-nitro-N-phenyl-1H-benzimidazol-2-amine 596130-91-5P
, tert-Butyl (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenylcarbamate
596130-92-6P, tert-Butyl (5-amino-1-methyl-1H-benzimidazol-2-yl)phenylcarbamate 596130-93-7P, tert-Butyl
[5-[[2-chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl]phenylcarbamate 596131-27-0P,
[5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)carbamate 596131-28-1P
, (4-Fluorophenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine
596131-29-2P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-fluorophenyl)carbamate 596131-30-5P,
[5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)carbamate 596131-31-6P,
[5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)carbamate 596131-32-7P,
(1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylamine
596131-33-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylcarbamate 596131-34-9P,
(5-Amino-1-methyl-1H-benzimidazol-2-yl)-p-tolylcarbamate 596131-35-0P, [5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-tert-butylphenyl)carbamate 596131-36-1P, (4-tert-Butylphenyl) [5-[[2-chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl]carbamate 596131-37-2P, (4-tert-Butylphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-38-3P, (4-tert-Butylphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)carbamate 596131-39-4P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-tert-butylphenyl)carbamate 596131-40-7P, (4-tert-Butylphenyl) [5-[[2-chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl]carbamate 596131-41-8P, N'-(2-Chloropyrimidin-4-yl)-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596131-42-9P, (4-Methoxyphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-43-0P, (4-Methoxyphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)carbamate 596131-44-1P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-methoxyphenyl)carbamate 596131-45-2P, [5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamate 596131-46-3P, [5-[[2-Chloropyrimidin-4-yl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamate 596131-74-7P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (4-fluorophenyl)carbamate 596133-27-6P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl)amine 596133-27-6P.

596133-29-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)(3-trifluoromethylphenyl)carbamic acid 1,1-dimethylethyl ester
 596133-31-2P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)(3-trifluoromethylphenyl)carbamic acid 1,1-dimethylethyl ester
 596133-33-4P, [5-[(2-Chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl](3-trifluoromethylphenyl)carbamic acid 1,1-dimethylethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)


RN 596130-89-1 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-90-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-phenyl- (CA INDEX NAME)




RN 596130-91-5 CAPLUS

CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-92-6 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-93-7 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-27-0 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl](4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-28-1 CAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-29-2 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)(4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-30-5 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-31-6 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl](4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-32-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-N-(4-methylphenyl)-5-nitro- (CA INDEX NAME)




RN 596131-33-8 CAPLUS

CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)(4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-34-9 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)(4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-35-0 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-36-1 CAPLUS


CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-37-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[4-(1,1-dimethylethyl)phenyl]-1-methyl-5-nitro-
 (CA INDEX NAME)




RN 596131-38-3 CAPLUS
 CN Carbamic acid, [4-(1,1-dimethylethyl)phenyl] (1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-39-4 CAPLUS
 CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) [4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-40-7 CAPLUS
 CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl] [4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-41-8 CAPLUS
 CN 1H-Benzimidazole-2,5-diamine, N5-(2-chloro-4-pyrimidinyl)-N2-(4-methoxyphenyl)-N5,1-dimethyl- (CA INDEX NAME)




RN 596131-42-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-1-methyl-5-nitro- (CA INDEX NAME)



RN 596131-43-0 CAPLUS
 CN Carbamic acid, (4-methoxyphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-44-1 CAPLUS
 CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-45-2 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-46-3 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-74-7 CAPLUS

CN Carbamic acid, (4-fluorophenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596133-27-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-29-8 CAPLUS

CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl) [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596133-31-2 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596133-33-4 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS
RECORD (17 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:142711 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 136:200200
TITLE: Preparation of imidazoquinazolinones as inhibitors of
tyrosine kinases
INVENTOR(S): Snow, Roger John; Gao, Donghong A.; Goldberg, Daniel
R.; Hammach, Abdelhakim; Kuzmich, Daniel; Morwick,
Tina Marie; Moss, Neil; Prokopowicz, Anthony S., III;
Selliah, Robert D.; Takahashi, Hidenori
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014319	A2	20020221	WO 2001-US24390	20010802 <--
WO 2002014319	A3	20020801		
W: CA, JP, MX RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2417635	A1	20020221	CA 2001-2417635	20010802 <--
CA 2417635	C	20080205		
US 20020119975	A1	20020829	US 2001-921510	20010802 <--
US 6489328	B2	20021203		
EP 1309596	A2	20030514	EP 2001-957425	20010802 <--
EP 1309596	B1	20080206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004506636	T	20040304	JP 2002-519459	20010802 <--
AT 385498	T	20080215	AT 2001-957425	20010802 <--
ES 2299501	T3	20080601	ES 2001-957425	20010802 <--
US 20030207902	A1	20031106	US 2002-271222	20021015 <--
US 6844435	B2	20050118		
MX 2003001306	A	20031015	MX 2003-1306	20030211 <--
PRIORITY APPLN. INFO.: US 2000-224724P P 20000811 <-- US 2001-921510 A3 20010802 <-- WO 2001-US24390 W 20010802 <--				


OTHER SOURCE(S): MARPAT 136:200200
IT 400784-57-8P 400784-58-9P 400784-59-0P
400784-60-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of imidazoquinazolinones as inhibitors of tyrosine kinases)
RN 400784-57-8 CAPLUS
CN 1H-Benzimidazole-7-carbonitrile, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-
methyl- (CA INDEX NAME)




RN 400784-58-9 CAPLUS
CN Acetamide, N-[7-cyano-2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-
benzimidazol-6-yl]- (CA INDEX NAME)



RN 400784-59-0 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-
methyl- (CA INDEX NAME)




RN 400784-60-3 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 2-[(2,6-dichlorophenyl)amino]-1-methyl-6-
[[{(2-propen-1-ylamino)thioxomethyl}amino]- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:699780 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 134:52473
TITLE: Syntheses and Properties of
1-Methyl-3-phenylaminobenzimidazolium Salts, Models of
DNA Adducts of N7-Arylamino deoxyguanosinium Salt
AUTHOR(S): Kaiya, Toyo; Fujiwara, Tomoko; Kohda, Kohfuku
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagoya City
University, Mizuho-ku Nagoya, 467-8603, Japan
SOURCE: Chemical Research in Toxicology (2000),
13(10), 993-1001
CODEN: CRTOEC; ISSN: 0893-228X
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 313486-00-9P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and methylation)
RN 313486-00-9 CAPLUS
CN 1H-Benzimidazol-1-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



IT 313486-01-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 313486-01-0 CAPLUS
CN 1H-Benzimidazolium, 1-methyl-5-nitro-3-(phenylamino)-, iodide (1:1) (CA
INDEX NAME)



● I⁻


OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:511140 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 131:157771
TITLE: Preparation of five-membered, benzo-condensed
heterocycles as antithrombotics
INVENTOR(S): Ries, Uwe; Haeu, Norbert; Mihm, Gerhard; Pripke,
Henning; Binder, Klaus; Stassen, Jean Marie; Wienen,
Wolfgang; Zimmermann, Rainer
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany
SOURCE: PCT Int. Appl., 250 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940072	A1	19990812	WO 1999-EP537	19990128 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
DE 19804085	A1	19990805	DE 1998-19804085	19980203 <--
DE 19834325	A1	20000217	DE 1998-19834325	19980730 <--
CA 2319494	A1	19990812	CA 1999-2319494	19990128 <--
AU 9927201	A	19990823	AU 1999-27201	19990128 <--
EP 1060166	A1	20001220	EP 1999-907437	19990128 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002502844	T	20020129	JP 2000-530502	19990128 <--
MX 2000005785	A	20010123	MX 2000-5785	20000612 <--
PRIORITY APPLN. INFO.:			DE 1998-19804085	A 19980203 <--
			DE 1998-19834325	A 19980730 <--
			WO 1999-EP537	W 19990128 <--

OTHER SOURCE(S): MARPAT 131:157771
IT 236416-21-0P 236416-22-1P 236416-27-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)
RN 236416-21-0 CAPLUS
CN Glycine, N-[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 236416-22-1 CAPLUS
CN Glycine, N-[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 236416-27-6 CAPLUS
CN Benzenecarboximidamide, 4-[[1-methyl-5-[(8-quinolinylsulfonyl)amino]-1H-benzimidazol-2-yl]amino]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


IT 236417-44-0P 236417-45-1P 236417-46-2P
236417-47-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)


RN 236417-44-0 CAPLUS
CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS
CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)



RN 236417-46-2 CAPLUS
CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 236417-47-3 CAPLUS
CN Glycine, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:505930 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 131:157761

TITLE: 5-Membered heterocyclic condensed benzo derivatives, their preparation, and their use as drugs

INVENTOR(S): Ries, Uwe; Haeuel, Norbert; Mihm, Gerhard; Priepke, Henning; Binder, Klaus; Stassen, Jean Marie; Wienen, Wolfgang; Zimmermann, Rainer

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: Ger. Offen., 94 pp.
CODEN: GWXXEX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19804085	A1	19990805	DE 1998-19804085	19980203 <--
CA 2319494	A1	19990812	CA 1999-2319494	19990128 <--
WO 9940072	A1	19990812	WO 1999-EP537	19990128 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9927201	A	19990823	AU 1999-27201	19990128 <--
EP 1060166	A1	20001220	EP 1999-907437	19990128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002502844	T	20020129	JP 2000-530502	19990128 <--
US 6114532	A	20000905	US 1999-243200	19990202 <--
MX 2000005785	A	20010123	MX 2000-5785	20000612 <--
PRIORITY APPLN. INFO.:				
DE 1998-19804085 A 19980203 <--				
US 1998-77694P P 19980312 <--				
DE 1998-19834325 A 19980730 <--				
WO 1999-EP537 W 19990128 <--				

OTHER SOURCE(S): MARPAT 131:157761

IT 236416-21-0P 236417-44-0P 236417-45-1P


236417-46-2P 236417-47-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and antithrombotic activity of
benzimidazolymethylbenzamidines)

RN 236416-21-0 CAPLUS


CN Glycine, N-[2-[[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolylsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 236417-44-0 CAPLUS

CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS

CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-46-2 CAPLUS

CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 236417-47-3 CAPLUS

CN Glycine, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester (CA INDEX NAME)




IT 236416-22-1P 237750-43-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antithrombotic activity of
benzimidazolymethylbenzamides)

RN 236416-22-1 CAPLUS


CN Glycine, N-[2-[[4-(aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 237750-43-5 CAPLUS

CN Benzenecarboximidamide, 4-[[1-methyl-5-[(8-quinolinylsulfonyl)amino]-1H-benzimidazol-2-yl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(10 CITINGS)

L5 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:806527 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 130:81512

TITLE: Preparation of benzoxazole, benzimidazole, and
benzothiazole compounds inhibiting production of
cytokine in type-2 helper T cell

INVENTOR(S): Tokunaga, Teruhisa; Fujita, Kazushi; Nagata, Ryu;
Ochi, Hiroshi; Watanabe, Takamasa; Nakatani, Tomosuke
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan; Sumitomo
Chemical Co., Ltd.

SOURCE: Jpn. Kokai Tokyo Koho, 336 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10330369	A	19981215	JP 1997-225679	19970806 <--
PRIORITY APPL. INFO.:			JP 1997-102481	A 19970404 <--
OTHER SOURCE(S):		MARPAT 130:81512		

IT 218621-62-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazole, benzimidazole, and benzothiazole compds.
inhibiting production of cytokine in type-2 helper T (Th2) cell for
treatment diseases related to hyperfunction of Th2 cells)


RN 218621-62-6 CAPLUS

CN Phenol, 5-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)


L5 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1992:511052 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 117:111052
ORIGINAL REFERENCE NO.: 117:19359a,19362a
TITLE: EPR study of nitroxyl radicals of substituted
5-anilino-1,2,4-triazoles, 5-anilino-1,2,4-tetrazoles, and
2-anilino-1,2,4-benzimidazoles
AUTHOR(S): Omelka, Ladislav; Meske, Michael; Cholvad, Vladimir;
Svetlik, Jan; Schulz, Manfred
CORPORATE SOURCE: Dep. Phys. Chem., Slovak Tech. Univ., Bratislava, 812
37, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (1992),
57(5), 1065-71
CODEN: CCCCAC; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 143017-91-8 143017-92-9
RL: PRP (Properties)
(ESR of)
RN 143017-91-8 CAPLUS
CN Nitroxide, 5-nitro-1H-benzimidazol-2-yl phenyl (9CI) (CA INDEX NAME)




RN 143017-92-9 CAPLUS
CN Nitroxide, 4-methoxyphenyl 5-nitro-1H-benzimidazol-2-yl (9CI) (CA INDEX NAME)



IT 86601-34-5 86601-36-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, with peroxy radical, nitroxide from)
RN 86601-34-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)




RN 86601-36-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)


L5 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:449687 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 115:49687
ORIGINAL REFERENCE NO.: 115:8633a,8636a
TITLE: Preparation of aminobenzimidazoles as dual inhibitors
of lipoxigenase and cyclooxygenase enzymes
INVENTOR(S): Stevens, Rodney W.; Masami, Nakane
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 419210	A1	19910327	EP 1990-310199	19900918 <--
EP 419210	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03109378	A	19910509	JP 1989-246732	19890922 <--
JP 06000759	B	19940105		
US 5141950	A	19920825	US 1990-583264	19900914 <--
AT 113586	T	19941115	AT 1990-310199	19900918 <--
ES 2062395	T3	19941216	ES 1990-310199	19900918 <--
CA 2025849	A1	19910323	CA 1990-2025849	19900920 <--
PRIORITY APPLN. INFO.:			JP 1989-246732	A 19890922 <--
OTHER SOURCE(S): MARPAT 115:49687				
IT 134869-16-2P	134869-17-3P	134869-18-4P		
134869-19-5P	134869-20-8P	134869-21-9P		
134869-22-0P	134869-25-3P	134869-26-4P		
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as lipoxigenase and cyclooxygenase inhibitor)				
RN 134869-16-2	CAPLUS			
CN 1H-Benzimidazole-2,6-diamine, N2-phenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)				




●2 HCl

RN 134869-17-3 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-18-4 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(2-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-19-5 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-20-8 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(4-butylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-21-9 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-1-naphthalenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-22-0 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N6-(phenylmethyl)-N2-3-pyridinyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 134869-25-3 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methoxyphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-26-4 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-methyl-N2-phenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

IT 134869-39-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive benzylation of, by benzaldehyde)
RN 134869-39-9 CAPLUS
CN 1H-Benzimidazole-2,6-diamine, N2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

L5 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:81830 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 114:81830
ORIGINAL REFERENCE NO.: 114:13976h,13977a
TITLE: Preparation of benzimidazole derivatives and analogs as antiulcer and cardiovascular agents
INVENTOR(S): Bru-Magniez, Nicole; Gungor, Timur; Lacrampe, Jean; Launay, Michele; Teulon, Jean Marie
PATENT ASSIGNEE(S): Laboratoires U.P.S.A., Fr.
SOURCE: Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW


DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 385850	A2	19900905	EP 1990-400537	19900227 <--
EP 385850	A3	19901219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2643903	A1	19900907	FR 1989-2833	19890303 <--
CA 2011222	A1	19900903	CA 1990-2011222	19900301 <--
AU 9050611	A	19900906	AU 1990-50611	19900302 <--
ZA 9001602	A	19901228	ZA 1990-1602	19900302 <--
JP 03014579	A	19910123	JP 1990-52567	19900303 <--
PRIORITY APPLN. INFO.: FR 1989-2833 A 19890303 <--				
OTHER SOURCE(S): CASREACT 114:81830; MARPAT 114:81830				
IT 131884-91-8P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antiulcer and cardiovascular agent)				
RN 131884-91-8 CAPLUS				
CN 1H-Benzimidazol-2-amine, 6-(1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)				




OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

L5 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:478244 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 113:78244
ORIGINAL REFERENCE NO.: 113:13239a,13242a
TITLE: Diheterocyclic compounds from dithiocarbamates and derivatives thereof. I.
2,2'-(Arylenediamino)bisbenzoxazoles,
2,2'-(arylenediamino)bis(imidazopyridines) and
8,8'-(arylenediamino)bisporines
AUTHOR(S): Garin, Javier; Melendez, Enrique; Merchan, Francisco L.; Merino, Pedro; Orduna, Jesus; Tejedor, Rosa; Tejero, Tomas
CORPORATE SOURCE: Inst. Cienc. Mater. Aragon, Univ. Zaragoza, Zaragoza, E-50009, Spain
SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 221-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:78244
IT 128587-22-4P 128587-27-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 128587-22-4 CAPLUS
CN 1,4-Benzenediamine, N1,N4-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)



RN 128587-27-9 CAPLUS
CN 1,4-Benzenediamine, 2-methyl-N1,N4-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1988:632046 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 109:232046
ORIGINAL REFERENCE NO.: 109:38399a,38402a
TITLE: Antioxidative efficiency of substituted N-phenyl N-pyrazolyl-3, N-phenyl N-benzimidazolyl-2, and N-benzthiazolyl-2 N-benzimidazolyl-2 amines in the thermooxidation of polypropylene
AUTHOR(S): Matisova-Rychla, L.; Rychly, J.; Meske, M.; Schulz, M.
CORPORATE SOURCE: Cent. Chem. Res., Slovak Acad. Sci., Bratislava, 842 36, Czech.
SOURCE: Polymer Degradation and Stability (1988), 21(4), 323-33
CODEN: PDSTDW; ISSN: 0141-3910
DOCUMENT TYPE: Journal
LANGUAGE: English


IT 86601-36-7

RL: USES (Uses)

(antioxidative efficiency of, in thermooxidn. of isotactic polypropylene)

RN 86601-36-7 CAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:539933 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 99:139933
ORIGINAL REFERENCE NO.: 99:21501a,21504a
TITLE: Heterocyclic diarylamine derivatives
INVENTOR(S): Serban, Alexander; Watson, Keith G.; Barton, John E. D.
PATENT ASSIGNEE(S): ICI Australia Ltd. , Australia
SOURCE: Can., 69 pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1145344	A1	19830426	CA 1980-347768	19800317 <--
AU 8055985	A	19800925	AU 1980-55985	19790319 <--
AU 534093	B2	19840105		
ZA 8001246	A	19810325	ZA 1980-1246	19800304 <--
HU 25187	A2	19830628	HU 1980-603	19800314 <--
HU 183116	B	19840428		
PRIORITY APPLN. INFO.:			AU 1979-8094	A 19790319 <--
			GB 1979-10365	A 19790412 <--
			AU 1979-8886	A 19790522 <--

IT 77206-07-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)


RN 77206-07-6 CAPLUS

CN Propanoic acid, 2-[4-[methyl(6-nitro-1H-benzimidazol-2-yl)amino]phenoxy]-, methyl ester (CA INDEX NAME)




L5 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:470625 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 99:70625
ORIGINAL REFERENCE NO.: 99:10967a,10970a
TITLE: A facile synthesis of dimethyl N-aryldithiocarbonimidates and 2-arylamino benzimidazoles
AUTHOR(S): Garin, J.; Melendez, E.; Merchan, F. L.; Tejel, C.; Tejero, T.
CORPORATE SOURCE: Dep. Quim. Org., Univ. Zaragoza, Zaragoza, Spain
SOURCE: Synthesis (1983), (5), 375-6
CODEN: SYNTBF; ISSN: 0039-7881


DOCUMENT TYPE: Journal
LANGUAGE: English
IT 86601-34-5P 86601-35-6P 86601-36-7P
86601-37-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86601-34-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)




RN 86601-35-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-methylphenyl)-6-nitro- (CA INDEX NAME)



RN 86601-36-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



RN 86601-37-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(3-chloro-2-methylphenyl)-6-nitro- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L5 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:156918 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 94:156918

ORIGINAL REFERENCE NO.: 94:25657a,25660a
TITLE: Herbicidal diarylamine derivatives
INVENTOR(S): Barton, John Edward Duncan; Serban, Alexander; Watson, Keith Geoffrey
PATENT ASSIGNEE(S): ICI Australia Ltd., Australia
SOURCE: Eur. Pat. Appl., 75 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 18080	A1	19801029	EP 1980-300793	19800314 <--
EP 18080	B1	19840314		
R: BE, CH, DE, FR, GB, IT, NL				
AU 8055985	A	19800925	AU 1980-55985	19790319 <--
AU 534093	B2	19840105		
ZA 8001246	A	19810325	ZA 1980-1246	19800304 <--
IL 59533	A	19850131	IL 1980-59533	19800305 <--
HU 25187	A2	19830628	HU 1980-603	19800314 <--
HU 183116	B	19840428		
US 4314065	A	19820202	US 1980-131389	19800317 <--
BR 8001618	A	19801118	BR 1980-1618	19800318 <--
JP 55149263	A	19801120	JP 1980-33480	19800318 <--
JP 04028701	B	19920515		
PRIORITY APPLN. INFO.:			AU 1979-8094	A 19790319 <--
			GB 1979-13065	A 19790412 <--
			AU 1979-8886	A 19790522 <--

OTHER SOURCE(S): CASREACT 94:156918
IT 77206-07-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)
RN 77206-07-6 CAPLUS
CN Propanoic acid, 2-[4-[methyl(6-nitro-1H-benzimidazol-2-yl)amino]phenoxy]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)


L5 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1973:58423 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 78:58423
ORIGINAL REFERENCE NO.: 78:9271a,9274a
TITLE: Anthelmintic isothiocyanatobenzothiazoles,- benzimidazoles, and -benzoxazoles
INVENTOR(S): Brenneisen, Paul; Wenger, Thomas; Gallay, Jean Jacques; Schmid, Wolfgang
PATENT ASSIGNEE(S): Ciba-Geigy A.-G.

SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2225071	A	19721207	DE 1972-2225071	19720523 <--
US 3840550	A	19741008	US 1972-255334	19720522 <--
BE 783791	A1	19721123	BE 1972-117737	19720523 <--
NL 7206929	A	19721128	NL 1972-6929	19720523 <--
FR 2138884	A1	19730105	FR 1972-18265	19720523 <--
ZA 7203514	A	19730328	ZA 1972-3514	19720523 <--
DD 98517	A5	19730620	DD 1972-163138	19720523 <--
US 3894037	A	19750708	US 1974-491585	19740724 <--
US 3933841	A	19760120	US 1974-491584	19740724 <--

PRIORITY APPLN. INFO.:
CH 1971-7542 A 19710524 <--
US 1972-255334 A3 19720522 <--
US 1974-255334 A3 19740522 <--

IT 39223-75-1P 39480-77-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39223-75-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-isothiocyanato-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 39480-77-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-6-isothiocyanato-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L5 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1964:418220 CAPLUS <<LOGINID:20091110>>
DOCUMENT NUMBER: 61:18220
ORIGINAL REFERENCE NO.: 61:3091d-f

TITLE: Carbonimidoyl dihalides as organic intermediates. I.
The preparation of 2-arylamino benzimidazoles
AUTHOR(S): Murphy, Daniel B.
CORPORATE SOURCE: City Univ. of New York, New York, NY
SOURCE: Journal of Organic Chemistry (1964), 29(6), 1613-15
CODEN: JOCEAH; ISSN: 0022-3263


DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 61:18220
IT 86601-34-5P, Benzimidazole, 2-anilino-5(or 6)-nitro-
97027-41-3P, Benzimidazole, 2-anilino-5-chloro-7-nitro-(?)
97028-28-9P, Benzimidazole,
6-chloro-2-(p-chloroanilino)-4-nitro-(?)
RL: PREP (Preparation)
(preparation of)
RN 86601-34-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



RN 97027-41-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 5-chloro-7-nitro-N-phenyl- (CA INDEX NAME)



RN 97028-28-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 5-chloro-N-(4-chlorophenyl)-7-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)


L5 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1962:13033 CAPLUS
DOCUMENT NUMBER: 56:13033
ORIGINAL REFERENCE NO.: 56:2457a-b

TITLE: Compounds containing both cyclic amidine and alkylene rings
 INVENTOR(S): Shen, Kwan Ting
 PATENT ASSIGNEE(S): Petrolite Corp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2987522		19610606	US 1958-721643	19580317 <--
IT 96170-15-9	96971-20-9	98422-81-2		
100628-77-1	101320-03-0	102345-66-4		
107541-46-8				

{Derived from data in the 7th Collective Formula Index (1962-1966)}

RN 96170-15-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 96971-20-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)(phenylmethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




●₂ HCl

RN 98422-81-2 CAPLUS
 CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7CI) (CA INDEX NAME)




RN 100628-77-1 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




●_x HCl

RN 101320-03-0 CAPLUS
 CN 2-Benzimidazolecarbamic acid, 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●_x HCl


RN 102345-66-4 CAPLUS
 CN Benzamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 107541-46-8 CAPLUS

CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● HCl

IT 101548-62-3P, p-Propionophenetidine,
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-
101548-63-4P, p-Propionophenetidine,
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride
RL: PREP (Preparation of)
(preparation of)


RN 101548-62-3 CAPLUS

CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)



RN 101548-63-4 CAPLUS

CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1962:13032 CAPLUS

DOCUMENT NUMBER: 56:13032

ORIGINAL REFERENCE NO.: 56:24551,2456a-i,2457a

TITLE: Benzimidazoles

INVENTOR(S): Hoffmann, Karl; Hunger, Alfred; Kebrie, Jindrich; Rossi, Alberto

PATENT ASSIGNEE(S): Ciba Pharmaceutical Products, Inc.

DOCUMENT TYPE: Patent


LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3000898		19580919	US	<--
GB 928154			GB	
PRIORITY APPLN. INFO.:			CH	19590831 <--
IT 94916-17-3P, Benzimidazole, 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro- Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidino- 95128-90-8P, Benzimidazole, 1-[2-(diethylamino)ethyl]-2-[N-(p-methoxyphenyl)acetamido]-5-nitro- 95698-89-8P, Benzimidazole, 2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-1-(2-piperidinoethyl)- 96167-31-6P, Benzimidazole, 1-[2-(dimethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro- 96167-54-3P, Benzimidazole, 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidino- Benzimidazole, 1-[2-(diethylamino)ethyl]-2-(N-ethyl-p-phenetidino)-5- nitro- 96309-87-4P, Benzimidazole, 1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro- 96971-20-9P, Benzimidazole, 2-(N-benzyl-p-phenetidino)-1-[2-(diethylamino)ethyl]-5-nitro- dihydrochloride 97297-44-4P, Benzimidazole, 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)- 97297-45-5P, Propionanilide, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]- 98422-81-2P, Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2- benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester 100176-34-9P, Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidino- hydrochloride 100260-95-5P, Benzimidazole, 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro-, hydrochloride				


100433-67-8P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-5-nitro-2-(N-phenylacetamido)-, hydrochloride
 100628-46-4P, Benzimidazole,
 1-[2-(dimethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-,
 hydrochloride 100628-59-9P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidino-, hydrochloride
 100628-77-1P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-2-(N-ethyl-p-phenetidino)-5-nitro-,
 hydrochloride 101016-59-5P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-,
 hydrochloride 101320-03-0P, 2-Benzimidazolecarbamic acid,
 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro, ethyl ester,
 hydrochloride 101548-62-3P, p-Propionophenetidine,
 N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-
 101548-63-4P, p-Propionophenetidine,
 N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride
 102345-66-4P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenylbenzamido)-5-nitro-,
 hydrochloride 104352-29-6P, Benzimidazole,
 1-[2-(diethylamino)ethyl]-2-[N-(p-methoxyphenyl)acetamido]-5-nitro-,
 hydrochloride 104763-43-1P, p-Formophenetidine,
 N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-
 104763-44-2P, p-Formophenetidine,
 N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride
 104763-51-1P, Propionanilide,
 N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride
 104763-77-1P, Benzimidazole,
 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)-, hydrochloride
 107541-46-8P, Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-
 benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride
 875832-28-3P, Benzimidazole,
 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro- 879654-71-4P,
 Benzimidazole, 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro-,
 hydrochloride
 RL: PREP (Preparation)
 (preparation of)
 RN 94916-17-3 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA
 INDEX NAME)





RN 94916-20-8 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-
 nitro- (CA INDEX NAME)




RN 95128-90-8 CAPLUS
 CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-
 methoxyphenyl)- (CA INDEX NAME)




RN 95698-89-8 CAPLUS
 CN Acetamide, N-(4-ethoxyphenyl)-N-[5-nitro-1-[2-(1-piperidiny)ethyl]-1H-
 benzimidazol-2-yl]- (CA INDEX NAME)




RN 96167-31-6 CAPLUS
 CN Acetamide, N-[1-[2-(dimethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-
 (4-ethoxyphenyl)- (CA INDEX NAME)




RN 96167-54-3 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-
 nitro- (CA INDEX NAME)




RN 96170-15-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RN 96309-87-4 CAPLUS
 CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)





RN 96971-20-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl) (phenylmethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




●₂ HCl


RN 97297-44-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 97297-45-5 CAPLUS
 CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-phenyl- (CA INDEX NAME)



RN 98422-81-2 CAPLUS
 CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7CI) (CA INDEX NAME)




RN 100176-34-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 100260-95-5 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 100433-67-8 CAPLUS
 CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 100628-46-4 CAPLUS
 CN Acetamide, N-[1-[2-(dimethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 100628-59-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 100628-77-1 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 101016-59-5 CAPLUS
 CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 101320-03-0 CAPLUS
 CN 2-Benzimidazolecarbamic acid, 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●x HCl


RN 101548-62-3 CAPLUS

CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)



RN 101548-63-4 CAPLUS


CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 102345-66-4 CAPLUS


CN Benzamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 104352-29-6 CAPLUS


CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 104763-43-1 CAPLUS

CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 104763-44-2 CAPLUS

CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)





● HCl

RN 104763-51-1 CAPLUS
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104763-77-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 107541-46-8 CAPLUS
CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● HCl

RN 875832-28-3 CAPLUS
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro- (CA INDEX NAME)



RN 879654-71-4 CAPLUS
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1962:12986 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 56:12986
ORIGINAL REFERENCE NO.: 56:2437g-i
TITLE: N-Acetylated pyrazolones
AUTHOR(S): Wahlberg, Erik
CORPORATE SOURCE: Univ. Uppsala, Swed.
SOURCE: Arkiv foer Kemi (1960), 17, 83-8
CODEN: ARKEAD; ISSN: 0365-6128



DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 IT 94916-20-8 96167-54-3 97297-44-4
 100176-34-9 100628-59-9 104763-77-1
 (Derived from data in the 7th Collective Formula Index (1962-1966))
 RN 94916-20-8 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RN 96167-54-3 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RN 97297-44-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 100176-34-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)





●x HCl

RN 100628-59-9 CAPLUS
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 104763-77-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1962:12985 CAPLUS <<LOGINID::20091110>>
 DOCUMENT NUMBER: 56:12985
 ORIGINAL REFERENCE NO.: 56:2436h-i,2437a-g

TITLE: Benzimidazole and related heterocycles. VII. New 2-aminobenzimidazoles

AUTHOR(S): Hunger, A.; Kebrle, J.; Rossi, A.; Hoffmann, K.

CORPORATE SOURCE: CIBA A.-G., Basel, Switz.

SOURCE: Helvetica Chimica Acta (1961), 44, 1273-82
CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: German


OTHER SOURCE(S): CASREACT 56:12985

IT 94916-17-3P, Benzimidazole, 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro- 94916-20-8P, Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidino- 96167-54-3P, Benzimidazole, 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidino- 97297-44-4P, Benzimidazole, 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)- 100176-34-9P, Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidino-, hydrochloride 100260-95-5P, Benzimidazole, 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro-, hydrochloride 100628-59-9P, Benzimidazole, 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidino-, hydrochloride 104763-77-1P, Benzimidazole, 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)-, hydrochloride 875832-28-3P, Benzimidazole, 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro- 879654-71-4P, Benzimidazole, 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro-, hydrochloride

RL: PREP (Preparation)
(preparation of)


RN 94916-17-3 CAPLUS

CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA INDEX NAME)




RN 94916-20-8 CAPLUS

CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)





RN 96167-54-3 CAPLUS

CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 97297-44-4 CAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 100176-34-9 CAPLUS


CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 100260-95-5 CAPLUS

CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)





●x HCl

RN 100628-59-9 CAPLUS
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




●x HCl

RN 104763-77-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 875832-28-3 CAPLUS
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro- (CA INDEX NAME)



RN 879654-71-4 CAPLUS
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1953:51359 CAPLUS <<LOGINID::20091110>>
DOCUMENT NUMBER: 47:51359
ORIGINAL REFERENCE NO.: 47:8669h-i,8670a-e
TITLE: Aromatic diazo compounds. VII. Coupling with m-phenylenediamine
AUTHOR(S): Muzik, Ferdinand; Allan, Zdenek J.
CORPORATE SOURCE: Chem. Research Inst., Pardubice-Rybitvi, Czech.
SOURCE: Chemicke Listy pro Vedu a Prumysl (1952), 277-80, 350-7
CODEN: CLPRAN; ISSN: 0366-6832
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

IT 853788-72-4P, Benzimidazole, 7-acetamido-1-p-chloroanilino-4-(p-chlorophenylazo)-2,6-dimethyl-
RL: PREP (Preparation)
(preparation of)

RN 853788-72-4 CAPLUS
CN Acetamide, N-[1-[(4-chlorophenyl)amino]-4-[2-(4-chlorophenyl)diazenyl]-2,6-dimethyl-1H-benzimidazol-7-yl]- (CA INDEX NAME)




L5 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1951:43092 CAPLUS
 DOCUMENT NUMBER: 45:43092
 ORIGINAL REFERENCE NO.: 45:7360f-i,7361a-b,7362a
 TITLE: Amino derivatives
 INVENTOR(S): Ackermann, Franz
 PATENT ASSIGNEE(S): C I B A Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2550321		19510424	US 1948-60400	19481116 <--


IT 855839-87-1P, Methanesulfonic acid,
 [[6-(sulfomethylamino)-2-benzimidazolyl]anilino]-
 RL: PREP (Preparation)
 (preparation of)
 RN 855839-87-1 CAPLUS
 CN Methanesulfonic acid, 1-[[6-(methylsulfoamino)-1H-benzimidazol-2-yl]phenylamino]- (CA INDEX NAME)




L5 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1924:12159 CAPLUS <<LOGINID::20091110>>
 DOCUMENT NUMBER: 18:12159
 ORIGINAL REFERENCE NO.: 18:1652d-i,1653a-g
 TITLE: Constitution of the reaction products from o-aminoazo


compounds and aldehydes. II
 AUTHOR(S): Fischer, Otto
 SOURCE: Journal fuer Praktische Chemie (Leipzig) (1924), 107, 16-49
 CODEN: JPCEAO; ISSN: 0021-8383
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 IT 861783-92-8, Benzimidazole, 5-amino-1-anilino-2-phenyl- (and derivs.)
 RN 861783-92-8 CAPLUS
 CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl- (CA INDEX NAME)




IT 861293-79-0P, Benzimidazole,
 1-(N-nitrosoanilino)-5-salicylal amino-2-salicyl- 861305-30-8P,
 Benzimidazole, 1-anilino-5-salicylal amino-2-salicyl-
 861305-32-0P, Benzimidazole, 1-anilino-5-benzalamino-2-phenyl-
 861783-94-0P, Benzimidazole,
 5-acetamido-1-(N-acetylanilino)-2-phenyl- 861800-49-9P,
 Benzimidazole, 5-benzalamino-1-(N-nitrosoanilino)-2-phenyl-
 RL: PREP (Preparation)
 (preparation of)
 RN 861293-79-0 CAPLUS
 CN Phenol, 2-[[5-[[[2-(hydroxyphenyl)methylene]amino]-1-(nitrosophenylamino)-1H-benzimidazol-2-yl]methyl]- (CA INDEX NAME)




RN 861305-30-8 CAPLUS
 CN Phenol, 2-[[5-[[[2-(hydroxyphenyl)methylene]amino]-1-(phenylamino)-1H-benzimidazol-2-yl]methyl]- (CA INDEX NAME)




RN 861305-32-0 CAPLUS
CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



RN 861783-94-0 CAPLUS
CN Acetamide, N-[5-(acetylamino)-2-phenyl-1H-benzimidazol-1-yl]-N-phenyl- (CA INDEX NAME)



RN 861800-49-9 CAPLUS
CN 1H-Benzimidazole-1,5-diamine, N1-nitroso-N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1913:8050 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 7:8050

ORIGINAL REFERENCE NO.: 7:1184d-1,1185a-e

TITLE: Substituted α -Hydroxy-and
 α -Methylbenzimidazoles

AUTHOR(S): Kym, O.; Ratner, L.

CORPORATE SOURCE: Univ. Zurich

SOURCE: Berichte der Deutschen Chemischen Gesellschaft (1913), 45, 3238-55

CODEN: BDCGAS; ISSN: 0365-9496

DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

IT 86601-34-5P, Benzimidazole, 2-anilino-5-nitro-

RL: PREP (Preparation)
(preparation of)

RN 86601-34-5 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



=> files tnguide

FILES IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

150.76

337.34

FILE 'STNGUIDE' ENTERED AT 09:17:46 ON 10 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 6, 2009 (20091106/UP).

=> log

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

(FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009)

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009

L1 STRUCTURE UPLOADED

D

L2 3 SEA FILE=REGISTRY SSS SAM L1

L3 586 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 09:13:01 ON 10 NOV 2009

L4 51 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L3

L5 36 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L4 AND (PD<20041027 OR
PRD<20041027 OR AD<20041027)
D 1-36 IBIB HITSTR